1. A 6-week-old infant born at 29 weeks gestational age is admitted with suspected bacterial meningitis. Blood cultures and CSF cultures are pending. The infant has a documented anaphylactic reaction to ampicillin at 3 weeks of age, and the neonatologist concludes that beta-lactam antibiotics cannot be used. A pharmacist calls to alert the team that a chloramphenicol order has been placed at the standard pediatric weight-based dose of 50 mg/kg/day divided every 6 hours. Which of the following represents the most appropriate immediate action?
A) Administer the ordered dose as written; the standard pediatric weight-based dose of 50 mg/kg/day is calculated to account for neonatal physiology and is safe across all gestational ages and postnatal ages without modification
B) Increase the dose to 75 mg/kg/day because premature neonates have higher volumes of distribution than term infants due to proportionally greater body water content, requiring higher weight-based doses to achieve therapeutic CSF concentrations
C) Reduce the dose substantially and initiate serum level monitoring; premature neonates have immature hepatic glucuronidation that markedly reduces chloramphenicol clearance, making the standard pediatric dose likely to produce toxic accumulation; the recommended dose for neonates is approximately 25 mg/kg/day with target peak levels below 25 mcg/mL to avoid cardiovascular toxicity from mitochondrial inhibition in cardiac muscle
D) Discontinue the chloramphenicol order and substitute trimethoprim-sulfamethoxazole (TMP-SMX), which has equivalent CNS penetration and no toxicity concerns in neonates of this gestational age
E) Administer the first dose as ordered and obtain a 2-hour post-dose serum chloramphenicol level; if the level is above 30 mcg/mL, reduce subsequent doses by 25%; if the level is within the range of 10 to 25 mcg/mL, continue the standard dose without further adjustment
ANSWER: C
Rationale:
This premature neonate is at high risk for gray baby syndrome if chloramphenicol is administered at the standard pediatric dose of 50 mg/kg/day. Gray baby syndrome results from accumulation of chloramphenicol to toxic concentrations due to immature hepatic glucuronidation — the primary metabolic pathway for chloramphenicol inactivation. Glucuronosyltransferase enzymes are developmentally immature in neonates and are particularly underdeveloped in premature infants; at 6 weeks postnatal age in a former 29-week premature infant, glucuronidation capacity remains substantially limited. Doses appropriate for older children produce toxic accumulation in this population. Chloramphenicol accumulating above approximately 25 mcg/mL inhibits mitochondrial protein synthesis in cardiac and skeletal muscle, producing the syndrome of abdominal distension, vomiting, cyanosis, ashen gray skin color, and cardiovascular collapse. The recommended approach when chloramphenicol is necessary in neonates is to use a substantially reduced dose of approximately 25 mg/kg/day with serum level monitoring targeting peak concentrations below 25 mcg/mL. Despite the toxicity risk, chloramphenicol remains a pharmacologically defensible choice here given the documented anaphylaxis to beta-lactams and the need for reliable CNS penetration.
Option A: Option A is incorrect because standard pediatric weight-based doses of 50 mg/kg/day are not safe in premature neonates; they are calculated for patients with mature metabolic pathways, and applying them to premature infants with immature glucuronidation is precisely the error that causes gray baby syndrome.
Option B: Option B is incorrect because increasing the dose would further raise plasma concentrations in a patient who is already unable to clear the drug at standard rates due to immature glucuronidation; higher volumes of distribution in neonates do not outweigh the risk of toxic accumulation from impaired clearance, and dose increases are contraindicated in this population.
Option D: Option D is incorrect because trimethoprim-sulfamethoxazole is contraindicated in premature neonates due to risk of kernicterus from bilirubin displacement from albumin, hyperbilirubinemia, and the immature renal handling of sulfonamides; it is not a safe substitute in this age group.
Option E: Option E is incorrect because waiting to obtain a 2-hour post-dose level after the first full 50 mg/kg/day dose may allow initial accumulation to begin; and the proposed threshold of 30 mcg/mL for dose reduction is above the level at which myelosuppression and cardiovascular toxicity begin; the correct approach is dose reduction before the first dose, not reactive adjustment after an initial toxic dose has been given.
2. A 68-year-old man with a seizure disorder (managed on phenytoin 300 mg daily, therapeutic level 14 mcg/mL) and atrial fibrillation (managed on warfarin, INR stable at 2.4) is admitted with a brain abscess caused by a beta-lactam-resistant anaerobic organism. The infectious disease team prescribes chloramphenicol based on its CNS penetration and anaerobic spectrum. Three days later the patient develops nystagmus, ataxia, and confusion; his phenytoin level is now 42 mcg/mL and his INR is 4.8. Which of the following best explains the primary mechanism responsible for both laboratory and clinical findings?
A) Chloramphenicol is a potent inhibitor of CYP2C19 and CYP2C9; phenytoin is primarily metabolized by CYP2C19 and its plasma concentration has more than doubled due to reduced hepatic clearance, producing the classic phenytoin toxicity syndrome of nystagmus, ataxia, and altered consciousness; S-warfarin is primarily metabolized by CYP2C9, and reduced warfarin clearance has enhanced anticoagulation, raising the INR to a supratherapeutic and bleeding-risk level; both findings share the unifying mechanism of chloramphenicol's CYP inhibitory activity
B) Chloramphenicol displaces both phenytoin and warfarin from plasma albumin binding sites, acutely increasing the free fractions of both drugs; the elevated total phenytoin and INR levels reflect this displacement effect rather than reduced clearance; free drug monitoring would show that free phenytoin and free warfarin levels have increased while total drug metabolic clearance is unchanged
C) Chloramphenicol induces hepatic CYP3A4, accelerating the metabolism of phenytoin to a toxic 5-hydroxyphenytoin metabolite that crosses the blood-brain barrier more efficiently than the parent compound; the elevated total phenytoin level reflects accumulation of this toxic metabolite rather than the parent drug; warfarin metabolism is accelerated by the same CYP3A4 induction, paradoxically reducing anticoagulation, and the elevated INR reflects rebound hypercoagulability from vitamin K accumulation
D) Chloramphenicol inhibits mitochondrial oxidative phosphorylation in hepatocytes, reducing cellular ATP production and impairing all energy-dependent metabolic processes in the liver; as a result, both phenytoin and warfarin accumulate due to globally impaired hepatic function rather than specific enzyme inhibition; this mechanism also explains the brain abscess patient's altered mental status as a direct hepatic encephalopathy from chloramphenicol-induced liver failure
E) The phenytoin toxicity and supratherapeutic INR result from pharmacodynamic synergy between chloramphenicol and each drug at their respective end-organ targets: chloramphenicol potentiates the sodium channel-blocking effect of phenytoin at neuronal membranes and simultaneously amplifies the vitamin K antagonist effect of warfarin at the gamma-carboxylation step, producing both neurological and anticoagulant toxicity through direct receptor interactions rather than pharmacokinetic changes
ANSWER: A
Rationale:
Both findings are explained by chloramphenicol's well-characterized inhibition of hepatic cytochrome P450 enzymes. Chloramphenicol is a potent inhibitor of CYP2C19, the primary isoform responsible for phenytoin metabolism (4-hydroxylation to the inactive metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin, or HPPH). By inhibiting CYP2C19, chloramphenicol reduces phenytoin clearance in a patient receiving a previously stable dose; phenytoin accumulates to toxic concentrations — more than tripling from 14 to 42 mcg/mL in this patient. Phenytoin toxicity at this level produces the classic cerebellar and vestibular findings of nystagmus, gait ataxia, and altered consciousness. Chloramphenicol also inhibits CYP2C9, the primary isoform responsible for metabolizing S-warfarin (the pharmacologically active enantiomer). Reduced S-warfarin clearance enhances the anticoagulant effect, raising the INR from 2.4 to 4.8 — a supratherapeutic and bleeding-risk level. Both interactions share the same mechanistic root: CYP enzyme inhibition reducing clearance of co-administered drugs that depend on those isoforms for hepatic metabolism. Management requires urgent reassessment of both anticoagulation and antiepileptic therapy with consideration of chloramphenicol substitution if an alternative antibiotic exists, or close monitoring with dose reductions of both phenytoin and warfarin if chloramphenicol must continue.
Option B: Option B is incorrect because while protein displacement can transiently increase free drug fractions, this mechanism does not produce the sustained and marked elevation in total phenytoin levels (from 14 to 42 mcg/mL) observed here; protein displacement typically produces modest changes in total drug levels that self-correct as free drug redistributes; the magnitude of the phenytoin level increase is consistent with reduced clearance, not displacement.
Option C: Option C is incorrect because chloramphenicol inhibits rather than induces CYP enzymes; it is an inhibitor of CYP2C19 and CYP2C9, not an inducer of CYP3A4; if CYP3A4 induction occurred, warfarin metabolism would be accelerated and the INR would decrease, not increase; and the toxic hydroxyphenytoin metabolite mechanism described is pharmacologically unsupported.
Option D: Option D is incorrect because chloramphenicol's mitochondrial toxicity in hepatocytes is not an established pharmacokinetic mechanism for its drug interactions; chloramphenicol interacts with phenytoin and warfarin through specific CYP enzyme inhibition, not through global hepatic ATP depletion; and the altered mental status in this patient is explained by phenytoin toxicity, not hepatic encephalopathy.
Option E: Option E is incorrect because the interactions between chloramphenicol and phenytoin or warfarin are pharmacokinetic (reduced hepatic clearance), not pharmacodynamic (end-organ receptor potentiation); chloramphenicol does not potentiate sodium channel blockade or vitamin K antagonism at their respective targets; this option conflates pharmacokinetic and pharmacodynamic interaction mechanisms.
3. A 71-year-old man with a long-term central venous catheter for total parenteral nutrition develops fever and rigors. Two sets of blood cultures drawn 12 hours apart both grow methicillin-resistant Staphylococcus aureus. A covering resident starts linezolid 600 mg IV every 12 hours, noting that linezolid was recently reported as superior to vancomycin in a clinical trial for MRSA infections. On hospital day 4, the patient remains febrile, blood cultures remain positive, and an echocardiogram reveals a 1.2 cm vegetation on the tricuspid valve. The infectious disease fellow is consulted. Which of the following best identifies the error in initial antibiotic selection and the appropriate correction?
A) Linezolid is an appropriate initial choice for MRSA bloodstream infection; the persistent bacteremia and endocarditis reflect inadequate source control rather than antibiotic failure, and the initial antibiotic selection should not be changed; central line removal is the only intervention needed
B) Linezolid should be replaced with daptomycin at a higher dose of 10 mg/kg/day for endocarditis; however, linezolid's failure here is pharmacokinetic rather than mechanistic — the drug distributes poorly into cardiac valve tissue, and daptomycin's unique mechanism of membrane depolarization allows it to penetrate fibrin vegetations
C) The correct initial antibiotic for MRSA bacteremia was vancomycin, not linezolid, because vancomycin has FDA approval for MRSA endocarditis while linezolid does not; the clinical trial superiority of linezolid over vancomycin applies equally to all anatomical sites including the bloodstream and cardiac valves
D) Linezolid failed because the MRSA isolate has developed resistance through accumulation of cfr gene mutations during the 4-day course; the correct response is to switch to tedizolid, which retains activity against cfr-positive isolates through its prodrug activation mechanism
E) Linezolid is bacteriostatic against Staphylococcus aureus including MRSA and is not appropriate for MRSA bacteremia or endocarditis, where bactericidal therapy is required to reliably clear organisms from the bloodstream and sterilize cardiac vegetations; the clinical trial that showed linezolid's superiority (the ZEPHYR trial) was specific to MRSA nosocomial pneumonia and does not apply to bloodstream infection; vancomycin or daptomycin should be substituted immediately
ANSWER: E
Rationale:
The fundamental error in this case is selecting a bacteriostatic agent for a bloodstream infection with endocarditis — a clinical scenario that requires bactericidal therapy. Linezolid is bacteriostatic against Staphylococcus aureus, including MRSA: it inhibits bacterial growth without reliably killing organisms. MRSA bacteremia, and especially MRSA endocarditis, requires bactericidal therapy to clear the bloodstream and to sterilize fibrin vegetations on cardiac valves, which are avascular structures dependent entirely on antibiotic diffusion and bactericidal killing for sterilization. Clinical trial evidence demonstrates inferior outcomes with linezolid compared to vancomycin and daptomycin for MRSA bacteremia. The ZEPHYR trial that showed linezolid's superiority over vancomycin was specifically conducted in MRSA nosocomial pneumonia (including ventilator-associated pneumonia); its results are driven by linezolid's superior penetration into pulmonary epithelial lining fluid and more predictable pharmacokinetics for the lung compartment. These results cannot be extrapolated to bacteremia or endocarditis. The appropriate management is immediate substitution of linezolid with a bactericidal agent — vancomycin with appropriate pharmacokinetic monitoring, or daptomycin (particularly at the higher dose of 8 to 10 mg/kg/day used for endocarditis) — combined with central line removal.
Option A: Option A is incorrect because the persistent bacteremia in this case is attributable to antibiotic selection error — linezolid's bacteriostatic activity against MRSA — not exclusively to inadequate source control; while central line removal is essential, it does not correct the fundamental pharmacological mismatch, and the antibiotic must be changed.
Option B: Option B is incorrect because the correct conclusion about daptomycin is right, but the stated reason for linezolid's failure is wrong — the failure is mechanistic (bacteriostatic vs. bactericidal), not pharmacokinetic poor cardiac distribution; linezolid does achieve adequate cardiac tissue concentrations, but bacteriostatic activity is insufficient for endocarditis regardless of tissue penetration.
Option C: Option C is incorrect because the clinical trial superiority of linezolid over vancomycin does not apply equally to all anatomical sites; ZEPHYR was specific to MRSA pneumonia, and the evidence for MRSA bacteremia and endocarditis shows the opposite — inferior outcomes with linezolid; and the framing around FDA approval rather than clinical evidence misrepresents the pharmacological basis of the prescribing principle.
Option D: Option D is incorrect because cfr gene resistance does not emerge after 4 days of linezolid therapy in a clinical MRSA infection; cfr is a horizontally acquired resistance determinant, not a mutation that accumulates within days; and tedizolid does not retain activity against cfr-positive isolates — cfr methylation at A2503 confers cross-resistance to all oxazolidinones.
4. A 64-year-old man undergoes an emergency exploratory laparotomy for perforated diverticulitis. On post-operative day 3 he develops fever to 38.9°C, leukocytosis, and purulent drainage from his wound. Gram stain of the wound drainage shows Gram-positive cocci in clusters and Gram-negative rods. The on-call surgical resident, aware that the patient had an allergic reaction to cephalexin in the past, writes an order for linezolid monotherapy based on its activity against MRSA. Cultures are sent and are pending. Which of the following best identifies the critical problem with this antibiotic order?
A) Linezolid is inappropriate for this wound infection because it is bacteriostatic against staphylococci, and all post-surgical wound infections require bactericidal therapy regardless of the infecting organism or the severity of illness
B) Linezolid has no clinically useful activity against Gram-negative organisms because it cannot penetrate the Gram-negative outer membrane; the Gram-negative rods visible on the Gram stain — which in a post-operative abdominal surgical wound could represent Enterobacteriaceae or even Pseudomonas aeruginosa — will be entirely unaddressed by linezolid monotherapy, creating a dangerous coverage gap that must be filled with an appropriate Gram-negative-active antibiotic
C) Linezolid is contraindicated in post-surgical patients because it inhibits monoamine oxidase, and the catecholamine vasopressors commonly used in post-operative hypotension interact with linezolid's MAOI activity to produce hypertensive crises that are uniformly fatal in the immediate post-operative period
D) Linezolid is inappropriate because the cephalexin allergy documented in this patient indicates a high likelihood of cross-reactivity to linezolid, as both drugs share a beta-lactam ring structure that mediates immune sensitization; a non-cross-reactive antibiotic such as vancomycin plus an aminoglycoside should be substituted
E) The critical problem is that linezolid's oral-only formulation cannot be used in post-operative patients who are NPO (nothing by mouth); because linezolid has no intravenous formulation, this order cannot be executed in a patient who cannot take oral medications in the immediate post-operative period
ANSWER: B
Rationale:
The critical problem with linezolid monotherapy in this patient is the spectrum gap for Gram-negative organisms. Linezolid is active exclusively against Gram-positive bacteria — its antimicrobial spectrum includes MRSA, VRE, and other Gram-positive pathogens, but it has no clinically useful activity against Gram-negative organisms. This is because oxazolidinones cannot efficiently penetrate the Gram-negative outer membrane, which acts as a permeability barrier preventing the drug from reaching the ribosomal target at intracellular concentrations needed for inhibition. The Gram stain clearly shows Gram-negative rods in addition to Gram-positive cocci; in a post-operative abdominal wound following diverticulitis, Gram-negative rods could represent Escherichia coli, Klebsiella pneumoniae, Enterobacter species, or Pseudomonas aeruginosa — all of which can cause serious wound infections and potentially sepsis if untreated. Linezolid monotherapy would leave this component entirely unaddressed. The correct approach is to add a Gram-negative-active antibiotic — such as a beta-lactam/beta-lactamase inhibitor combination, a fluoroquinolone (if susceptibility is likely and allergy history permits), or a carbapenem — to provide the necessary coverage. A cephalexin allergy does not necessarily preclude all beta-lactams, and the allergy history should be evaluated for its nature and severity before excluding the entire class.
Option A: Option A is incorrect because linezolid is an accepted treatment for some serious Gram-positive wound infections including MRSA skin and soft tissue infections; the bacteriostatic-versus-bactericidal distinction is a reason to avoid linezolid specifically for bacteremia and endocarditis, not an absolute contraindication for all wound infections regardless of severity; the primary issue here is the spectrum gap, not the bacteriostatic property.
Option C: Option C is incorrect because while linezolid does have MAOI activity and can interact with serotonergic agents and some indirect sympathomimetics, the described interaction producing uniformly fatal hypertensive crises with all post-operative catecholamine vasopressors is an overstatement; this concern, while real for certain combinations, is not the primary pharmacological error in this order, which is the spectrum gap for Gram-negative coverage.
Option D: Option D is incorrect because linezolid is not a beta-lactam antibiotic and does not share any structural features with cephalexin; a cephalexin allergy has no pharmacological basis for predicting cross-reactivity to linezolid; the two drugs belong to entirely different antibiotic classes with no shared chemical determinants for immune sensitization.
Option E: Option E is incorrect because linezolid is available in both oral and intravenous formulations; it is one of the few antibiotics where the oral and IV formulations are therapeutically equivalent at the same dose due to approximately 100% oral bioavailability; IV linezolid can be administered to patients who are NPO.
5. A 57-year-old woman with major depressive disorder maintained on escitalopram 20 mg daily is admitted with vancomycin-resistant Enterococcus faecium (VRE) bacteremia. Echocardiography reveals a mitral valve vegetation consistent with infective endocarditis. The team reviews antibiotic options; daptomycin susceptibility testing is pending and ampicillin MIC confirms high-level resistance. An intern proposes linezolid as empiric therapy, noting that linezolid is active against VRE. The infectious disease attending raises two independent pharmacological objections. Which of the following best identifies both objections?
A) Linezolid is objectionable because it requires intravenous administration only for endocarditis, making outpatient oral step-down impossible; and it produces myelosuppression that would dangerously reduce white blood cell count in a patient with active endocarditis who requires an intact immune response to clear the vegetation
B) Linezolid is objectionable because its Gram-positive spectrum does not include Enterococcus faecium; VRE endocarditis caused by E. faecium specifically requires a glycopeptide-class antibiotic because linezolid lacks the necessary enterococcal activity regardless of vancomycin resistance status
C) Linezolid is objectionable because escitalopram inhibits linezolid's renal clearance, causing linezolid to accumulate to supratherapeutic levels that produce myelosuppression; and because linezolid's once-daily dosing does not achieve bactericidal concentrations against VRE in cardiac vegetations
D) Linezolid is objectionable on two independent grounds: its MAO inhibitory activity combined with escitalopram's serotonin reuptake inhibition creates a pharmacodynamic risk for potentially life-threatening serotonin syndrome; and linezolid is bacteriostatic against enterococci, making it pharmacologically inadequate for endocarditis, which requires bactericidal therapy to sterilize avascular cardiac vegetations
E) Linezolid is objectionable because escitalopram is metabolized by CYP2C19, and linezolid's CYP2C19 inhibition will cause escitalopram accumulation producing QTc prolongation and torsades de pointes; and because linezolid penetrates cardiac valve tissue poorly due to its large molecular weight, making achievable concentrations insufficient for VRE eradication
ANSWER: D
Rationale:
The attending's two independent pharmacological objections reflect two distinct properties of linezolid that are each independently sufficient to warrant serious concern in this patient. The first objection is pharmacodynamic: linezolid is a reversible, nonselective MAO inhibitor (MAOI) that reduces the degradation of serotonin, dopamine, and norepinephrine by inhibiting monoamine oxidase. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake from the synapse. When both mechanisms operate simultaneously — reduced degradation via MAOI and reduced reuptake via SSRI — synaptic serotonin accumulates and can produce serotonin syndrome, characterized by mental status changes, autonomic instability, and neuromuscular abnormalities including clonus and hyperreflexia. Serotonin syndrome can be life-threatening. The second objection is microbiological/pharmacodynamic: linezolid is bacteriostatic against enterococci, including VRE. Infective endocarditis requires bactericidal therapy — fibrin vegetations are avascular and depend entirely on antibiotic diffusion followed by bactericidal killing for sterilization; bacteriostatic agents that inhibit growth without killing cannot reliably sterilize vegetations, and clinical outcomes for endocarditis treated with bacteriostatic agents are inferior. These two concerns are independent — either alone would prompt reconsideration — and together they make linezolid a poor choice for this patient pending daptomycin susceptibility results.
Option A: Option A is incorrect because linezolid does have both IV and oral formulations with approximately 100% oral bioavailability, and oral step-down is possible; and while myelosuppression is a real concern with prolonged linezolid therapy, the primary objections to its use here are serotonin syndrome risk and bacteriostatic activity against enterococci, not immune suppression.
Option B: Option B is incorrect because linezolid does have activity against Enterococcus faecium, including VRE — this is one of its primary clinical indications; describing it as lacking enterococcal activity regardless of vancomycin resistance status is pharmacologically incorrect.
Option C: Option C is incorrect because escitalopram does not inhibit linezolid renal clearance through any established pharmacokinetic mechanism; linezolid is not primarily renally cleared through transporters inhibited by escitalopram; and linezolid is dosed 600 mg every 12 hours, not once daily.
Option E: Option E is incorrect because linezolid does not inhibit CYP2C19 to a clinically meaningful extent; it is not metabolized by CYP enzymes and does not produce CYP-mediated drug interactions; the interaction between linezolid and escitalopram is pharmacodynamic through the serotonin pathway, not pharmacokinetic through CYP2C19 inhibition.
6. A 48-year-old woman with MRSA osteomyelitis of the lumbar vertebrae has been receiving linezolid 600 mg orally every 12 hours for 7 weeks. Weekly laboratory monitoring shows a platelet count declining from 190,000/mcL at baseline to 88,000/mcL this week. On review of systems, she also reports new bilateral foot numbness and tingling that began approximately 10 days ago and has been gradually worsening. Visual acuity testing shows no changes at this time. Which of the following best characterizes both complications and identifies the correct prioritization of the clinical response?
A) Both the thrombocytopenia and the peripheral neuropathy reflect linezolid's inhibition of mitochondrial protein synthesis; thrombocytopenia is fully reversible upon drug discontinuation and represents a manageable adverse effect requiring drug reassessment; peripheral neuropathy, however, may progress to irreversible axonal damage if linezolid is continued, and the new neurological symptoms represent an urgent indication to discontinue linezolid promptly and explore alternative MRSA-active regimens — the potential irreversibility of neuropathy makes it the more clinically urgent of the two findings
B) The thrombocytopenia is the more urgent concern because a platelet count of 88,000/mcL creates immediate risk of spontaneous intracranial hemorrhage requiring platelet transfusion; the peripheral neuropathy is a known and fully reversible side effect of linezolid that typically resolves within 2 to 3 days of drug discontinuation and does not require treatment modification at this stage
C) Both findings are expected and acceptable during prolonged linezolid therapy; the thrombocytopenia reflects the drug's known effect on rapidly dividing cells and will stabilize at this level; the paresthesias are caused by direct compression of lumbar nerve roots from the vertebral osteomyelitis itself rather than linezolid toxicity, and imaging should be obtained before attributing them to the antibiotic
D) Neither finding requires medication change; the thrombocytopenia is within an acceptable range for outpatient monitoring, and the paresthesias most likely represent diabetic peripheral neuropathy or vitamin B12 deficiency rather than linezolid toxicity; stopping linezolid prematurely would risk recurrence of the vertebral osteomyelitis
E) Both findings indicate that the patient has developed aplastic anemia from prolonged linezolid use; the mechanism is identical to chloramphenicol aplastic anemia, involving idiosyncratic destruction of hematopoietic stem cells and simultaneous neurological toxicity from nitroso-linezolid metabolites; bone marrow biopsy is required immediately and the patient should be referred for bone marrow transplantation evaluation
ANSWER: A
Rationale:
Both thrombocytopenia and peripheral neuropathy in this patient result from linezolid's inhibition of mitochondrial protein synthesis, but they differ critically in their reversibility and therefore in the urgency of the clinical response. Thrombocytopenia from linezolid is dose- and duration-dependent, affects megakaryocyte precursors in the bone marrow, and is fully reversible when the drug is discontinued — platelets typically recover within weeks. A count of 88,000/mcL warrants serious consideration of drug change, but the reversibility means the window for recovery remains open as long as the drug is stopped before more severe thrombocytopenia develops. Peripheral neuropathy from linezolid occurs with prolonged therapy, typically courses exceeding 4 to 6 weeks, and results from mitochondrial dysfunction in peripheral neurons and potentially retinal ganglion cells. Unlike the reversible myelosuppression in rapidly regenerating marrow cells, peripheral neurons are post-mitotic with extremely limited regenerative capacity; continued linezolid exposure may produce structural axonal damage that is not reversible even after drug discontinuation. The 10-day history of worsening bilateral paresthesias in a patient on 7 weeks of linezolid should be treated as urgent — every additional day of linezolid exposure risks progression from a potentially reversible functional impairment to permanent structural neural damage. Monthly ophthalmological and neurological monitoring is the standard recommendation for courses exceeding 4 weeks specifically because early detection and prompt discontinuation are the only tools available to prevent irreversibility. The absence of visual changes is reassuring but does not reduce urgency. The priority action is to discontinue linezolid and seek alternative MRSA-active therapy (such as daptomycin, trimethoprim-sulfamethoxazole, or minocycline depending on susceptibility).
Option B: Option B is incorrect because it reverses the urgency: a platelet count of 88,000/mcL does not create immediate risk of spontaneous intracranial hemorrhage — that risk is generally associated with counts below 10,000 to 20,000/mcL; and describing peripheral neuropathy as fully reversible within 2 to 3 days misrepresents the clinical reality that neuropathy from prolonged linezolid may be irreversible, requiring months if it resolves at all.
Option C: Option C is incorrect because attributing the paresthesias to lumbar nerve root compression from the osteomyelitis without considering linezolid toxicity in a patient on 7 weeks of therapy represents a dangerous diagnostic anchoring error; vertebral osteomyelitis can cause radiculopathy, but bilateral foot paresthesias in a patient on prolonged linezolid must prompt evaluation for drug toxicity before being attributed to structural disease.
Option D: Option D is incorrect because neither finding can be safely ignored; thrombocytopenia at 88,000/mcL that has been declining weekly requires action, and new peripheral paresthesias at 7 weeks of linezolid therapy require urgent evaluation and likely drug discontinuation rather than attribution to unrelated causes.
Option E: Option E is incorrect because linezolid does not cause idiosyncratic aplastic anemia — that toxicity is specific to chloramphenicol; linezolid causes reversible dose-dependent myelosuppression, which is mechanistically distinct from chloramphenicol aplastic anemia; and the described nitroso-linezolid metabolite neurological toxicity mechanism is not established pharmacology.
7. A neonatologist is treating a 3-week-old former 32-week premature infant with confirmed bacterial meningitis caused by a beta-lactam-resistant organism. The decision has been made to use chloramphenicol at a reduced neonatal dose of 25 mg/kg/day with serum level monitoring. The pharmacist asks the neonatologist to consider whether the oral or intravenous formulation is preferred in this patient, given that the infant is currently tolerating enteral feeds. Which of the following best explains the pharmacokinetic rationale for preferring oral chloramphenicol over the intravenous formulation in a neonate who can tolerate enteral administration?
A) Oral chloramphenicol is preferred because gastrointestinal absorption is slower in neonates than in adults, providing a controlled-release effect that reduces peak plasma concentrations and lowers the risk of acute cardiac toxicity from sudden high drug levels; intravenous administration delivers the full dose immediately, producing dangerously steep concentration peaks that overwhelm the immature neonatal cardiac mitochondria
B) Oral chloramphenicol is preferred because enteral administration activates a specialized intestinal drug transporter in neonates that converts chloramphenicol to a less toxic glucuronide form during absorption, reducing systemic toxicity compared to intravenous delivery of the unconjugated drug
C) Oral chloramphenicol base is the active compound and is absorbed directly from the gastrointestinal tract with approximately 75 to 90% bioavailability, producing more predictable plasma concentrations than the intravenous formulation; intravenous chloramphenicol is formulated as the succinate prodrug, which requires hydrolysis by plasma and tissue esterases before releasing active drug — hydrolysis that is variable and often incomplete, particularly in neonates with immature esterase activity, resulting in less predictable active drug levels from the same administered dose
D) Oral chloramphenicol is preferred because the neonatal gastrointestinal tract provides a pharmacokinetic buffer that limits peak chloramphenicol concentrations; intravenous chloramphenicol succinate is converted to the active form so rapidly in neonates that peak plasma levels are consistently 3 to 4 times higher than with oral dosing at the same weight-based dose
E) There is no clinically meaningful difference between oral and intravenous chloramphenicol in neonates; both formulations produce identical plasma concentration-time profiles because neonatal intestinal P-glycoprotein expression is negligible, eliminating the efflux that limits oral bioavailability in older patients; the choice between routes should be based on venous access availability rather than pharmacokinetic considerations
ANSWER: C
Rationale:
Oral chloramphenicol base is the active drug in its absorbed form and is taken up from the gastrointestinal tract with approximately 75 to 90% bioavailability, producing reasonably predictable plasma concentrations of active chloramphenicol. Intravenous chloramphenicol, in contrast, is formulated as chloramphenicol succinate — a water-soluble ester prodrug that must be hydrolyzed by plasma and tissue esterases to release active chloramphenicol. This hydrolysis step is variable and frequently incomplete even in adults, with a portion of the succinate ester excreted unchanged in the urine before conversion occurs. In neonates, esterase activity may be further reduced due to developmental immaturity, making hydrolysis even more unpredictable. The clinical consequence is that the actual plasma concentration of active chloramphenicol generated from an IV dose of the succinate formulation is difficult to predict from the administered dose alone — it may be lower than expected if hydrolysis is poor (risking subtherapeutic concentrations for meningitis) or higher if conversion is efficient. In a neonate who can tolerate enteral feeds, oral chloramphenicol base therefore provides more predictable drug exposure and is pharmacokinetically preferable, provided serum level monitoring is used to confirm therapeutic concentrations given the background limitation of immature glucuronidation.
Option A: Option A is incorrect because the rationale described — slower enteral absorption providing a controlled-release protective effect — is not the pharmacokinetic basis for preferring oral administration; while peak concentrations may be somewhat lower with oral dosing, the primary advantage is predictability of the active drug concentration, not rate control; and the described acute cardiac mitochondrial toxicity from IV peak levels is not the established mechanism of concern at correctly dosed IV chloramphenicol.
Option B: Option B is incorrect because there is no specialized intestinal drug transporter in neonates that converts chloramphenicol to a glucuronide form during absorption; glucuronidation occurs in the liver, not in the intestinal wall, and neonatal intestinal absorption does not provide a protective conjugation effect.
Option D: Option D is incorrect because the premise that IV chloramphenicol succinate is converted to active drug 3 to 4 times faster in neonates than with oral dosing is not supported by the pharmacokinetic evidence; the problem with IV succinate in neonates is variable and often incomplete hydrolysis (producing lower and less predictable levels), not accelerated conversion producing higher peaks.
Option E: Option E is incorrect because there is a clinically meaningful pharmacokinetic difference between oral and IV chloramphenicol: the IV formulation is a prodrug requiring hydrolysis, while the oral formulation is the active compound absorbed directly; P-glycoprotein efflux is not the primary factor explaining differences in chloramphenicol bioavailability between routes.
8. A 77-year-old ventilated patient in the medical ICU has MRSA ventilator-associated pneumonia. She has been on vancomycin for 5 days with trough levels maintained at 15 to 20 mcg/mL, but shows no clinical improvement — she remains febrile, her chest radiograph is worsening, and repeat bronchoalveolar lavage cultures continue to grow MRSA with a vancomycin MIC of 1.5 mcg/mL. The infectious disease team is considering switching to linezolid. Simultaneously, two sets of blood cultures drawn this morning are reported as pending at 18 hours of incubation. Which of the following represents the most pharmacologically sound approach?
A) Switch immediately to linezolid without waiting for blood culture results; the ZEPHYR trial confirmed linezolid's superiority to vancomycin for all serious MRSA infections, and the blood culture results are irrelevant to the antibiotic selection decision for this patient with confirmed pneumonia
B) Continue vancomycin and add rifampin as a synergistic partner; rifampin's ability to penetrate lung parenchyma at high concentrations will provide the additional bactericidal activity needed to clear the MRSA pneumonia without the risks associated with linezolid
C) Switch to daptomycin, which has superior lung penetration compared to both vancomycin and linezolid; daptomycin achieves pulmonary epithelial lining fluid concentrations 10 times higher than plasma levels in ventilated patients, making it the preferred agent for MRSA ventilator-associated pneumonia based on pharmacokinetic data
D) Increase the vancomycin dose to achieve AUC/MIC of greater than 600; the vancomycin MIC of 1.5 mcg/mL is below the resistance threshold, and inadequate drug exposure rather than vancomycin failure is the most likely explanation for the lack of clinical response
E) The switch to linezolid is pharmacologically appropriate for this MRSA pneumonia given the clinical evidence supporting its superiority to vancomycin for this indication, including better pulmonary epithelial lining fluid penetration and more predictable pharmacokinetics; however, the pending blood cultures must be reviewed before the switch is confirmed — if bacteremia is present, linezolid is inappropriate due to its bacteriostatic activity against MRSA, and a bactericidal agent would be required for the bloodstream component
ANSWER: E
Rationale:
This question requires integrating two pieces of clinical pharmacology: linezolid's demonstrated superiority to vancomycin for MRSA pneumonia and its contraindication for MRSA bacteremia. The ZEPHYR trial demonstrated that linezolid outperformed vancomycin for MRSA nosocomial pneumonia — including ventilator-associated pneumonia — driven by linezolid's superior penetration into pulmonary epithelial lining fluid (achieving concentrations several times higher than simultaneous plasma levels) and more predictable pharmacokinetics compared to vancomycin's renal function-dependent dosing. This patient — with confirmed MRSA VAP, vancomycin MIC of 1.5 mcg/mL, and clinical failure on vancomycin — is a reasonable candidate for linezolid. However, the blood culture results pending at 18 hours are clinically critical before completing the switch decision. Patients with MRSA pneumonia can develop concurrent bacteremia, and bacteremia would change the management fundamentally: linezolid is bacteriostatic against MRSA and produces inferior outcomes for MRSA bloodstream infections. If blood cultures return positive for MRSA, linezolid monotherapy would be insufficient for the bacteremia component even if appropriate for the pneumonia. The correct approach is therefore: proceed with the plan to switch to linezolid as appropriate for the pneumonia, but hold final implementation until blood culture results are known; if bacteremia is confirmed, a bactericidal agent for the bloodstream must be added or substituted.
Option A: Option A is incorrect because the ZEPHYR trial's superiority data for linezolid are specific to MRSA pneumonia and do not extend to all serious MRSA infections including bacteremia; blood culture results are directly relevant to antibiotic selection in a patient who may have concurrent bacteremia; dismissing them as irrelevant represents a potentially dangerous clinical oversight.
Option B: Option B is incorrect because adding rifampin to vancomycin for MRSA pneumonia is not supported by clinical evidence as a standard approach, and the rationale about rifampin lung penetration exceeding that of linezolid is not pharmacokinetically accurate; rifampin should generally not be added empirically to MRSA regimens without susceptibility testing.
Option C: Option C is incorrect because daptomycin is actually inactivated by pulmonary surfactant and is not recommended for MRSA pneumonia; its use is specifically cautioned against for pulmonary infections; characterizing it as having superior lung penetration for VAP is pharmacologically incorrect.
Option D: Option D is incorrect because modern vancomycin AUC/MIC-guided dosing does involve targeting AUC/MIC ratios greater than 400 to 600, but in a patient with documented clinical failure after 5 days of adequate vancomycin exposure and a creeping MIC of 1.5 mcg/mL, continued vancomycin intensification is not the appropriate response; switching to linezolid is supported by the clinical evidence.
9. A 34-year-old patient is receiving linezolid 600 mg twice daily as part of a multi-drug regimen for extensively drug-resistant tuberculosis (XDR-TB). He has been on this regimen for 4 months and has been tolerating it with only mild thrombocytopenia (platelet count 110,000/mcL). At his monthly visit he reports that over the past 3 weeks he has noticed progressive blurring of central vision and difficulty distinguishing red from green. His platelet count today is 98,000/mcL. Fundoscopic examination is pending. Which of the following best identifies the most urgent action required and its pharmacological justification?
A) Increase the pyridoxine (vitamin B6) supplementation dose from the current 50 mg daily to 200 mg daily; optic changes at this stage reflect reversible pyridoxine deficiency from linezolid's inhibition of B6-dependent enzymes, and higher-dose supplementation will reverse the visual symptoms within 2 to 4 weeks without requiring drug discontinuation
B) Linezolid must be discontinued promptly; the progressive central visual blurring and color vision disturbance represent linezolid-associated optic neuropathy caused by mitochondrial dysfunction in retinal ganglion cells — the same mechanism as the myelosuppression but in a post-mitotic cell type with extremely limited regenerative capacity; unlike the reversible thrombocytopenia, optic neuropathy may progress to permanent vision loss if linezolid is continued, and delay in drug discontinuation directly worsens the prognosis for visual recovery
C) Continue linezolid and obtain urgent MRI of the brain and orbits; the visual symptoms and color vision loss in a patient with active tuberculosis most likely represent optic chiasm compression from tuberculoma or paradoxical immune reconstitution inflammatory syndrome (IRIS) rather than drug toxicity, and antibiotic discontinuation without confirming the cause would risk XDR-TB progression
D) Reduce the linezolid dose to 300 mg twice daily; the visual symptoms indicate early mitochondrial toxicity that is fully reversible with dose reduction without requiring full discontinuation; maintaining a sub-toxic dose allows continued XDR-TB treatment while the visual symptoms are expected to resolve over 4 to 6 weeks at the lower dose
E) Continue the current linezolid regimen and monitor visual acuity monthly; the described visual changes are below the threshold for action at this stage because central visual blurring and color vision changes do not constitute clinically significant optic neuropathy until confirmed by formal visual field testing showing a central scotoma of greater than 10 degrees; initiating linezolid discontinuation before formal confirmation would prematurely terminate a critical component of the XDR-TB regimen
ANSWER: B
Rationale:
The new-onset progressive central visual blurring and color vision disturbance in a patient who has been on linezolid for 4 months represents a neurological emergency that requires prompt drug discontinuation. Linezolid-associated optic neuropathy is a well-recognized complication of prolonged therapy. It results from mitochondrial dysfunction in retinal ganglion cells — the same mechanism responsible for linezolid's myelosuppressive effects and peripheral neuropathy, arising from the drug's inhibition of mitochondrial protein synthesis. Unlike bone marrow hematopoietic precursors (which are rapidly regenerating and allow full platelet and red cell recovery after drug discontinuation), retinal ganglion cells are post-mitotic neurons with essentially no regenerative capacity in adults. Mitochondrial damage that is not halted promptly by drug discontinuation may progress to irreversible structural injury of the retinal ganglion cells, producing permanent central visual field loss. The progressive nature of symptoms over 3 weeks — color vision disturbance and central blurring — is the classic early presentation of linezolid optic neuropathy. Guidelines for linezolid use in prolonged regimens (such as XDR-TB, where courses of 6 to 24 months are used) specifically recommend monthly ophthalmological monitoring to detect this complication early because early discontinuation is the only intervention that preserves the possibility of recovery; continued exposure beyond symptom onset is directly correlated with worse visual outcomes. While the loss of one component of the XDR-TB regimen is clinically challenging, the risk of permanent blindness from continued linezolid exposure outweighs the benefit of maintaining the current regimen without modification.
Option A: Option A is incorrect because pyridoxine supplementation is used in XDR-TB patients on linezolid as a prophylactic measure to potentially mitigate neuropathy risk through an incompletely understood mechanism, but it is not the treatment for established optic neuropathy; once optic neuropathy is clinically evident, pyridoxine dose escalation alone is insufficient and drug discontinuation remains the essential intervention.
Option C: Option C is incorrect because while tuberculous CNS involvement and IRIS are real diagnostic considerations, the occurrence of progressive visual symptoms in a patient on 4 months of linezolid mandates urgent evaluation of drug toxicity; the clinical picture — bilateral central color vision loss and blurring at 4 months of linezolid — is highly characteristic of linezolid optic neuropathy, and waiting for imaging results while continuing linezolid risks permanent vision loss.
Option D: Option D is incorrect because dose reduction to 300 mg twice daily is not a validated management strategy for established linezolid optic neuropathy; there is no clinical evidence that halving the dose reliably halts or reverses established optic neuropathy, and the mitochondrial damage in post-mitotic retinal ganglion cells may continue even at reduced drug levels.
Option E: Option E is incorrect because waiting for formal visual field testing to confirm a central scotoma before acting is not the appropriate clinical standard; progressive subjective visual symptoms and color vision changes in a patient on prolonged linezolid therapy are actionable findings that require drug discontinuation now — not after a threshold criterion is met — because delay directly worsens the prognosis for visual recovery.
10. A 66-year-old immunocompromised patient develops a urinary tract infection that progresses to bacteremia caused by Enterococcus faecium. Susceptibility testing returns: vancomycin resistant, linezolid resistant (MIC 16 mcg/mL), daptomycin susceptible. The microbiology report notes that the isolate carries the cfr gene. The infectious disease fellow asks whether tedizolid could be used as an alternative oxazolidinone given that tedizolid is more potent than linezolid and retains activity against some linezolid-resistant isolates. Which of the following is the most accurate response?
A) Tedizolid is the correct choice; cfr-positive isolates retain susceptibility to tedizolid because the phosphatase-mediated prodrug activation step generates an active moiety with a different chemical structure than linezolid that is not affected by cfr-mediated ribosomal methylation; tedizolid MIC testing is not required because cfr-positive status predicts full tedizolid susceptibility
B) Tedizolid is the correct choice because the cfr gene encodes methylation at position A2503, which specifically blocks linezolid binding at the A site of the 50S subunit; tedizolid binds at a completely separate location on the 23S rRNA outside the peptidyl transferase region, making cfr methylation irrelevant to tedizolid's mechanism and ensuring full activity regardless of cfr status
C) Tedizolid is likely to be active because cfr only confers clinically significant resistance to oxazolidinones when the MIC exceeds 8 mcg/mL; the linezolid MIC of 16 mcg/mL in this isolate reflects chromosomal 23S rRNA point mutations rather than cfr, and cfr-mediated resistance does not affect tedizolid at standard doses
D) Tedizolid is not expected to be active against this cfr-positive isolate; the cfr gene encodes an rRNA methyltransferase that methylates adenine at position A2503 in the 23S rRNA, a modification that reduces binding affinity for all drugs in the oxazolidinone class by disrupting the overlapping binding region shared by both linezolid and tedizolid; tedizolid may retain activity against isolates with single 23S rRNA point mutations, but cfr-mediated methylation confers cross-class resistance to oxazolidinones that tedizolid's higher potency does not overcome; daptomycin, which has a completely different mechanism of action, is the appropriate agent
E) Tedizolid cannot be used for enterococcal bacteremia because it is only approved for acute bacterial skin and skin structure infections; using tedizolid for bacteremia caused by any organism is an off-label application that is not supported by any clinical trial data, and the pharmacological properties of tedizolid in the bloodstream are unknown
ANSWER: D
Rationale:
This question requires applying knowledge of cfr resistance to a clinical decision about whether to substitute tedizolid for linezolid. Tedizolid does retain activity against some linezolid-resistant isolates — specifically those with single point mutations in the 23S rRNA gene (e.g., at positions 2447, 2504, or 2576). In these cases, tedizolid's higher intrinsic potency (approximately 4 to 8 times lower MIC than linezolid against wild-type organisms) allows it to remain above the MIC even after the single-copy mutation reduces binding affinity. However, cfr represents a qualitatively different resistance mechanism. The cfr gene encodes an rRNA methyltransferase that methylates the adenine residue at position A2503 in the 23S rRNA of the 50S subunit. This single modification alters the conformation of the peptidyl transferase region in a way that reduces binding affinity for all drugs in the oxazolidinone class — including both linezolid and tedizolid — because both drugs bind at or near this region on the 50S subunit. Tedizolid's higher intrinsic potency does not overcome this modification; the resistance is qualitative (target site alteration that reduces affinity for the entire drug class) rather than quantitative (a potency shift that tedizolid's higher baseline activity could overcome). The correct treatment for this patient is daptomycin, which is susceptible and acts by an entirely different mechanism — membrane depolarization — that is unaffected by ribosomal methylation.
Option A: Option A is incorrect because tedizolid's prodrug activation by phosphatases does not generate a chemical structure that bypasses cfr-mediated methylation; the active tedizolid moiety binds to the same ribosomal region as linezolid, and cfr methylation affects both; cfr-positive status does not predict tedizolid susceptibility.
Option B: Option B is incorrect because tedizolid and linezolid bind to overlapping regions of the 23S rRNA in the peptidyl transferase loop, not at completely separate locations; cfr methylation at A2503 affects the binding region of both drugs; describing tedizolid as binding outside the peptidyl transferase region is pharmacologically inaccurate.
Option C: Option C is incorrect because cfr does produce clinically significant resistance to tedizolid, and the distinction described based on linezolid MIC level to differentiate cfr from chromosomal mutations is not a validated clinical interpretation rule; cfr-positive status on molecular testing is an independent predictor of tedizolid resistance regardless of the linezolid MIC value.
Option E: Option E is incorrect because tedizolid's off-label use for serious Gram-positive infections including bacteremia has been described in clinical practice and case series; characterizing its pharmacological properties in bacteremia as entirely unknown overstates the regulatory approval limitation; however, the correct reason tedizolid is not the answer here is resistance, not approval status.
11. A 29-year-old man presents to the emergency department with severe headache, fever, neck stiffness, and photophobia. Lumbar puncture reveals cloudy CSF with a WBC of 2,800 cells/mcL (predominantly neutrophils), glucose of 28 mg/dL (serum glucose 98 mg/dL), and protein of 420 mg/dL. Gram stain of the CSF shows Gram-negative diplococci. His medication allergy list documents anaphylaxis to penicillin G (throat swelling, hypotension) and a severe urticarial reaction to cefepime. Blood cultures are drawn and empiric antibiotic therapy must be started immediately. Which of the following antibiotic choices is most pharmacologically appropriate given the allergy history and the clinical presentation?
A) Vancomycin plus meropenem; meropenem is a carbapenem with negligible cross-reactivity to penicillin despite being a beta-lactam, and adding vancomycin provides additional Gram-positive coverage while awaiting culture results and sensitivities
B) Azithromycin; as a macrolide antibiotic structurally unrelated to beta-lactams, azithromycin has no cross-reactivity risk and its anti-inflammatory properties reduce meningeal cytokine production; macrolides achieve adequate CSF concentrations in patients with inflamed meninges
C) Chloramphenicol; its exceptional CNS penetration — achieving CSF concentrations of approximately 30 to 50% of plasma even without meningeal inflammation — combined with bactericidal activity against Neisseria meningitidis at achievable clinical concentrations makes it pharmacologically appropriate for bacterial meningitis in a patient with documented anaphylaxis to penicillin and severe reaction to a cephalosporin
D) Linezolid; as an oxazolidinone with approximately 100% oral bioavailability and good CSF penetration of approximately 66 to 70% of plasma concentrations in meningitis, linezolid provides Gram-positive and Gram-negative coverage through its unique pre-initiation ribosomal block mechanism, making it appropriate for empiric meningitis coverage when beta-lactams cannot be used
E) Doxycycline; as a tetracycline antibiotic completely unrelated to beta-lactams, doxycycline carries no cross-reactivity risk and achieves CSF concentrations adequate for treatment of Neisseria meningitidis meningitis; tetracyclines are the preferred alternative class for meningococcal meningitis in beta-lactam-allergic patients according to current guidelines
ANSWER: C
Rationale:
The clinical presentation — Gram-negative diplococci in CSF, neutrophilic pleocytosis, low CSF glucose, high protein, and meningismus — is consistent with Neisseria meningitidis meningitis (meningococcal disease). This patient has documented anaphylaxis to penicillin G and severe urticaria to cefepime (a cephalosporin), which effectively excludes the use of all beta-lactam antibiotics including penicillins, cephalosporins, and (in this clinical context of severe documented reactions) carbapenems given the potential for cross-reactivity. Chloramphenicol is pharmacologically well-suited for this indication for two reasons that operate together. First, it achieves CSF concentrations of approximately 30 to 50% of simultaneous plasma levels even without meningeal inflammation, and approaches plasma concentrations when meninges are inflamed — a degree of CNS penetration achieved by passive diffusion due to its lipophilic, un-ionized structure, superior to most beta-lactam alternatives. Second, chloramphenicol is bactericidal (not merely bacteriostatic) against Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae at clinically achievable concentrations — the three most common bacterial causes of community-acquired meningitis. These two pharmacological properties together make chloramphenicol a rational and defensible choice for bacterial meningitis in patients who cannot receive beta-lactams.
Option A: Option A is incorrect because carbapenems, including meropenem, are beta-lactam antibiotics; while the cross-reactivity rate between carbapenems and penicillins is lower than between cephalosporins and penicillins, a patient with documented penicillin anaphylaxis and cephalosporin severe reaction represents a high-risk profile where carbapenem administration carries meaningful cross-reactivity risk and would typically be avoided; this option does not adequately address the allergy concern.
Option B: Option B is incorrect because azithromycin achieves negligible CSF concentrations and is not an established treatment for bacterial meningitis caused by N. meningitidis; while macrolides have some anti-inflammatory properties, they are not bactericidal against meningeal pathogens at CSF concentrations achievable in clinical practice; azithromycin is used for meningococcal prophylaxis in some settings but not for treatment of meningococcal meningitis.
Option D: Option D is incorrect because linezolid has no clinically useful activity against Gram-negative organisms including N. meningitidis; its spectrum is restricted to Gram-positive bacteria; and characterizing its mechanism as providing Gram-negative coverage misrepresents its spectrum, which would leave the confirmed Gram-negative pathogen untreated.
Option E: Option E is incorrect because doxycycline does not achieve reliable therapeutic CSF concentrations for bacterial meningitis; tetracyclines are not a recommended treatment class for meningococcal meningitis in any current guideline for beta-lactam-allergic patients; characterizing doxycycline as preferred for meningococcal meningitis in beta-lactam-allergic patients is pharmacologically unsupported.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.